# Empagliflozin, a sodium glucose cotransporter-2 inhibitor, ameliorates peritoneal fibrosis via suppressing TGF-β/Smad signaling

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/empagliflozin-a-sodium-glucose-cotransporter-2-inhibitor-ameliorates-peritoneal/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Yangping Shentu,Yuyang Li,Shicheng Xie,Huanchang Jiang,Shicheng Sun,Rixu Lin,Chaosheng Chen,Yongheng Bai,Yu Zhang,Chenfei Zheng,Ying Zhou |
| Citations | 52 |
| DOI | 10.1016/j.intimp.2021.107374 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W3128186009 |
| PMID | 33517222 |
| Type | article |
| Year | 2021 |

## Paper authors

- [Ying Zhou](https://scholariq.org/researchers/ying-zhou/)

## Paper journal

- [International Immunopharmacology](https://scholariq.org/journals/international-immunopharmacology/)

## Paper primary topic

- [Dialysis and Renal Disease Management](https://scholariq.org/topics/dialysis-and-renal-disease-management/)

## Paper topics

- [Dialysis and Renal Disease Management](https://scholariq.org/topics/dialysis-and-renal-disease-management/)
- [Parathyroid Disorders and Treatments](https://scholariq.org/topics/parathyroid-disorders-and-treatments/)
- [Pancreatitis Pathology and Treatment](https://scholariq.org/topics/pancreatitis-pathology-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.